Century Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview

Century Therapeutics

11/08/2026 14:30

Century Therapeutics, Inc. IPSC.OQ IPSC.O is expected to  show no change in quarterly revenue when it reports  results on August 13 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Century Therapeutics, Inc. is for a loss of 11 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Century Therapeutics, Inc. is $5.00, about 152.5% above its last closing price of $1.98
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.15
-0.16
-0.11
Beat
30.4
Dec. 31 2026
-0.28
-0.28
-0.22
Beat
22.4
Sep. 30 2025
-0.31
-0.34
-0.32
Beat
5.2​
Jun. 30 2025
-0.38
-0.38
-0.38
Met
-1.1
​​Mar. 31 2025
0.05
0.06
0.89
Beat
1,518.2
Dec. 31 2024
-0.42
-0.43
Missed
-1.9​
Sep. 30 2024
-0.44
-0.45
-0.37
Beat
17.4
Jun. 30 2024
-0.47
-0.46
-0.38
Beat
17.6
This summary was machine generated August 11 at 13:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)